Literature DB >> 32270353

Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy.

Maria Paola Belfiore1, Alfonso Reginelli2, Nicola Maggialetti3, Mattia Carbone4, Sabrina Giovine5, Antonella Laporta6, Fabrizio Urraro1, Valerio Nardone7, Roberta Grassi1, Salvatore Cappabianca1, Luca Brunese3.   

Abstract

Cholangiocarcinoma (CC) accounts for about 3% of the gastrointestinal and 10-25% of all hepatobiliary malignancies. It arises from the epithelium of the bile duct and it can be classified in intrahaepatic (ICC), perihilar (PCC) and distal (DCC) cholangiocarcinoma, depending on the anatomical location. About 50-60% of the cases are PCC. Early detection is very difficult for the lack of symptoms, and most of the patients are not resectable at the time of diagnosis. IRE is a non-thermal ablation technique that determines cellular apoptosis by electrical impulses without involving extracellular matrix like MW or RF ablation (MWA and RFA). The aim of our study is to demonstrate the safety, feasibility and efficacy of this procedure in the treatment of cholangiocarcinoma according to our experience. From 2015 to 2019, fifteen patients with unre-sectable perhilar and intrahepatic colangiocarcinoma (7 female and 8 male, mean age 69.2) were referred to our department to be enrolled in our prospective study that was approved by local Ethical Committee. Eight lesions were defined iCC and seven of them pCC. Six patients had biliary STENT and four external percutaneous transhepatic biliary drainage (PTBD). The IRE procedure was performed to expert radiologist (G.B.) under CT guidance using the Nanoknife IRE device (Angiodynamics, Queensbury, NY). The data before and after treatment were compared using Wilcoxon Rank Test and the survival outcome was evaluated using Kaplan Meyer Test. All procedures performed under CT guidance have been successfully completed. Treated lesions were located seven perhilar and eight intrahepatic sites and showed a mean volume 66.3 (SD 70.9; IC ranged from 5.57 to 267.20 cm3). No major complications were observed. From 30 to 90 days, the mortality rate was around 0%. Progression of the disease in all cases were not observed. Only one patient was reported increase of the Ca19-9 without sign of pancreatitis and bile obstruction. The imaging follow-up showed the local disease control with a decrease of the entire volume of the lesion and a further reduction of the densitometric values. From the comparison between the mean volumes for each group (before and after treatment), the Wilcoxon Rank test demonstrated the statistical significant difference with a p value < 0.01. On the contrary, it is believed that this results encouraging in considering the IRE procedure the safe, feasible and effective method in the treatment of the CC.

Entities:  

Keywords:  Cholangiocarcinoma; Cholangiography-MRI; IRE; Intrahepatic-CC; MWA; Perihepatic-CC; RFA

Year:  2020        PMID: 32270353     DOI: 10.1007/s12032-020-01360-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

1.  Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.

Authors:  Maria Paola Belfiore; Francesco Michele Ronza; Francesco Romano; Giovanni Pietro Ianniello; Guido De Lucia; Concetta Gallo; Carmela Marsicano; Teresa Letizia Di Gennaro; Giuseppe Belfiore
Journal:  Int J Surg       Date:  2015-06-25       Impact factor: 6.071

Review 2.  Vascular and interventional radiology radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: literature review.

Authors:  Irene Chiara De Bernardi; Chiara Floridi; Alessandra Muollo; Roberta Giacchero; Gian Lorenzo Dionigi; Alfonso Reginelli; Gianluca Gatta; Vito Cantisani; Roberto Grassi; Luca Brunese; Gianpaolo Carrafiello
Journal:  Radiol Med       Date:  2014-06-14       Impact factor: 3.469

Review 3.  Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature.

Authors:  Icro Meattini; Isacco Desideri; Giulio Francolini; Agnese Vannini; Marco Perna; Pietro Garlatti; Roberta Grassi; Lorenzo Livi
Journal:  Med Oncol       Date:  2017-03-31       Impact factor: 3.064

Review 4.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

5.  Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma.

Authors:  Emily K Martin; Neal Bhutiani; Michael E Egger; Prejesh Philips; Charles R Scoggins; Kelly M McMasters; Lawrence R Kelly; Gary C Vitale; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2018-07-26       Impact factor: 3.647

6.  Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer.

Authors:  Giuseppe Belfiore; Maria Paola Belfiore; Alfonso Reginelli; Raffaella Capasso; Francesco Romano; Giovanni Pietro Ianniello; Salvatore Cappabianca; Luca Brunese
Journal:  Med Oncol       Date:  2017-02-04       Impact factor: 3.064

Review 7.  Locoregional Therapies of Cholangiocarcinoma.

Authors:  Christof M Sommer; Hans U Kauczor; Philippe L Pereira
Journal:  Visc Med       Date:  2016-12-05

Review 8.  Irreversible electroporation of hepatic malignancy.

Authors:  Govindarajan Narayanan; Tatiana Froud; Rekhaben Suthar; Katuska Barbery
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 9.  Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.

Authors:  Hester J Scheffer; Karin Nielsen; Marcus C de Jong; Aukje A J M van Tilborg; Jenny M Vieveen; Arthur R A Bouwman; Sybren Meijer; Cornelis van Kuijk; Petrousjka M P van den Tol; Martijn R Meijerink
Journal:  J Vasc Interv Radiol       Date:  2014-03-18       Impact factor: 3.464

10.  The Influence of a Metal Stent on the Distribution of Thermal Energy during Irreversible Electroporation.

Authors:  Hester J Scheffer; Jantien A Vogel; Willemien van den Bos; Robert E Neal; Krijn P van Lienden; Marc G H Besselink; Martin J C van Gemert; Cees W M van der Geld; Martijn R Meijerink; John H Klaessens; Rudolf M Verdaasdonk
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

View more
  7 in total

Review 1.  Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?

Authors:  Yifan Wang; Mario Strazzabosco; David C Madoff
Journal:  Curr Oncol Rep       Date:  2022-10-18       Impact factor: 5.945

Review 2.  Basic embolization techniques: tips and tricks.

Authors:  Anna Maria Ierardi; Filippo Piacentino; Filippo Pesapane; Aldo Carnevale; Marco Curti; Federico Fontana; Massimo Venturini; Antonio Pinto; Francesco Gentili; Susanna Guerrini; Massimo De Filippo; Melchiore Giganti; Gianpaolo Carrafiello
Journal:  Acta Biomed       Date:  2020-07-13

3.  The role of imaging in surgical planning for liver resection: what the radiologist need to know.

Authors:  Andrea Agostini; Alessandra Borgheresi; Chiara Floridi; Marina Carotti; Giulia Grazzini; Francesco Pagnini; Susanna Guerrini; Pierpaolo Palumbo; Silvia Pradella; Gianpaolo Carrafiello; Marco Vivarelli; Andrea Giovagnoni
Journal:  Acta Biomed       Date:  2020-07-13

Review 4.  Hepatic tumors: pitfall in diagnostic imaging.

Authors:  Giulia Grazzini; Diletta Cozzi; Federica Flammia; Roberta Grassi; Andrea Agostini; Maria Paola Belfiore; Alessandra Borgheresi; Maria Antonietta Mazzei; Chiara Floridi; Gianpaolo Carrafiello; Andrea Giovagnoni; Silvia Pradella; Vittorio Miele
Journal:  Acta Biomed       Date:  2020-07-13

Review 5.  An overview of the irreversible electroporation for the treatment of liver metastases: When to use it.

Authors:  Maria Paola Belfiore; Marco De Chiara; Alfonso Reginelli; Alfredo Clemente; Fabrizio Urraro; Roberto Grassi; Giuseppe Belfiore; Salvatore Cappabianca
Journal:  Front Oncol       Date:  2022-09-01       Impact factor: 5.738

6.  USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3.

Authors:  Weiqian Chen; Jingjing Song; Siyu Liu; Bufu Tang; Lin Shen; Jinyu Zhu; Shiji Fang; Fazong Wu; Liyun Zheng; Rongfang Qiu; Chunmiao Chen; Yang Gao; Jianfei Tu; Zhongwei Zhao; Jiansong Ji
Journal:  J Biomed Sci       Date:  2021-06-10       Impact factor: 8.410

Review 7.  Interventional Treatment for Cholangiocarcinoma.

Authors:  Hang Li; Li Chen; Guang-Yu Zhu; Xijuan Yao; Rui Dong; Jin-He Guo
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.